Prestige Consumer Healthcare Inc.
NYSE:PBHMedical - Distribution
+$0.23 today
- Market cap
- $2.40B
- Beta
- 0.35
- P/E (TTM)
- 11.6
- EPS (TTM)
- $4.01
Volume 0.62M
Average 0.67M
PBH Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Prestige Consumer Healthcare Inc.NYSE: PBH
Net Margin · Q1 FY2027 · quarter ended Jun 2026
Net margin narrows to 11.0%
Net margin was 11.0% in Q1 FY2027, down 8.0 pp from a year earlier. On a trailing-twelve-month basis it was 15.6%, down 3.4 pp year over year. Over 3 fiscal years it widened by 24.8 pp.
Context
- Net margin widened in 2 of the last 3 fiscal years.
What to watch
Whether net margin reaches the consensus estimate from 6 analysts of 17.2% for the fiscal year ending Mar 2027, down from 17.5% in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 11.0%-8.2 pp QoQ
- Last fiscal yearMar 2026
- 17.5%-1.4 pp YoY
- LTMJun 2026
- 15.6%-3.4 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -8.0 pp | +0.1 pp | +8.2 pp |
| 1 year | -1.4 pp | -0.3 pp | +1.1 pp |
| 3 years | +24.8 pp | +1.2 pp | -23.6 pp |
| 5 years | +3.0 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2026
- 17.5%
- Year-over-year change
- -1.4pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 17.5% | -1.4pp |
| FY2025 | 2025-03-31 | 18.9% | +0.3pp |
| FY2024 | 2024-03-31 | 18.6% | +25.9pp |
| FY2023 | 2023-03-31 | -7.3% | -26.2pp |
| FY2022 | 2022-03-31 | 18.9% | — |
Net Margin vs competitors
How PBH compares with its peers on the latest reported figures
- PBH's LTM Jun 2026 net margin of 15.6% is the 2nd highest of the 10 companies compared; the peer median is 1.2%.
- Its year-over-year change of -3.4 pp is the lowest of 10, against a peer median of +7.8 pp.
- Over three fiscal years its change of +24.8 pp compares with a peer median of +2.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 37.1% | +0.2 pp | -2.4 pp | |
| LTM Jun 2026 | 15.6% | -3.4 pp | +24.8 pp | |
| LTM Sep 2026 | 13.0% | +29.1 pp | -9.0 pp | |
CONConcentra Group Holdings Parent, Inc. | LTM Sep 2026 | 9.3% | +1.9 pp | -2.0 pp |
| LTM Jun 2026 | 1.4% | +3.0 pp | +3.3 pp | |
| LTM Jun 2026 | 1.2% | +0.4 pp | +1.7 pp | |
| LTM Sep 2026 | -0.0% | +26.4 pp | +352.6 pp | |
| LTM Mar 2026 | -15.9% | +9.8 pp | +24.4 pp | |
HTFLHeartflow, Inc. Common Stock | LTM Sep 2026 | -33.1% | +44.3 pp | — |
| LTM Jun 2026 | -41.9% | +7.8 pp | +168.0 pp | |
IRONDisc Medicine, Inc. | FY2025 | — | — | — |
| Peer median (excluding PBH) | 1.2% | +7.8 pp | +2.5 pp | |
Competitors are the stored peer set for PBH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 1.09B | 1.13B | 1.13B | 1.14B | 1.09B |
| Cost of Revenue | 466.17M | 502.43M | 500.91M | 503.3M | 514.07M |
| Gross Profit | 620.65M | 625.29M | 624.45M | 634.46M | 574.64M |
| Gross Margin | 57.1% | 55.4% | 55.5% | 55.8% | 52.8% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 264.8M | 252.42M | 259.47M | 263.93M | 265.23M |
| Operating Expenses | 290.73M | 647.71M | 282.02M | 297.69M | 265.23M |
| Depreciation & Amortization | 32.09M | 32.63M | 30.68M | 30.17M | 31.27M |
| EBITDA | 358.84M | 7.87M | 373.86M | 361.99M | 331.11M |
| EBITDA Margin | 33.0% | 0.7% | 33.2% | 31.8% | 30.4% |
| Operating Income | 329.92M | (22.42M) | 342.43M | 336.78M | 309.41M |
| Operating Margin | 30.4% | -2.0% | 30.4% | 29.6% | 28.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 64.29M | 69.16M | 67.16M | 47.63M | 42.34M |
| Other Income / Expenses | (67.46M) | (71.5M) | (66.4M) | (52.59M) | (51.91M) |
| Income Before Tax | 262.46M | (93.92M) | 276.03M | 284.19M | 257.5M |
| Pre-Tax Margin | 24.1% | -8.3% | 24.5% | 25.0% | 23.7% |
| Income Tax Expense | 57.08M | (11.61M) | 66.69M | 69.58M | 67.2M |
| Net Income | 205.38M | (82.31M) | 209.34M | 214.61M | 190.3M |
| Net Margin | 18.9% | -7.3% | 18.6% | 18.9% | 17.5% |
| EPS (Basic) | 4.09 | (1.65) | 4.21 | 4.32 | 3.93 |
| EPS (Diluted) | 4.04 | (1.65) | 4.17 | 4.29 | 3.91 |
| Weighted Avg Shares | 50.26M | 49.88M | 49.76M | 49.7M | 48.46M |
| Weighted Avg Shares (Diluted) | 50.84M | 49.89M | 50.18M | 50.08M | 48.72M |
Prestige Consumer Healthcare Inc.
NYSE:PBH
Intrinsic Alpha fair value
Locked
Current Price
$50.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.